Indication
In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node-positive) NSCLC and no known EGFR mutations or ALK rearrangements.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2677
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 09 December 2024
- SMC meeting date:
- 05 November 2024
- Patient group submission deadline:
- 01 October 2024